Supplementary Materails:

Table S1. Survival outcomes of patients with a diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms in retrospective studies where median survival estimates by Kaplan-Meier analysis were not reached.

Reference	Total N patients	Median follow- up time	Localised stage	Advanced stage	
Nie L., 2016	14	17 m	 4 recurred and died after 8, 8, 10 and 11m 8 free from recurrence and alive after 9, 12, 12, 12, 28, 30, 30 and 43m 1 lost to follow-up 	1 free from progression and alive after 18m	
Düzköylü Y., 2018	10	15m	 6 alive after 3, 10, 20, 26, 31, and 51m 3 died after 3, 10 and 22m 	1 died after 5m	
La Rosa S., 2018	14	6.5 yrs	 12 free from recurrence/progression and alive after 1, 1, 2, 2, 2, 4, 9, 11, 12, 12, 24 and 27 yrs 2 lost to follow-up 		
Dulskas, A. 2019	9	17m	• 3 alive after 20, 28 and 56m	 2 alive after 11 and 18m 4 died after 2, 11, 14 and 17m 	

yrs = years; m = months; N= number.

Table S2. Comparison of survival outcomes of mixed neuroendocrine non-neuroendocrine neoplasms with survival outcomes of other neoplasms from the same sites of origin.

Reference	Site	MiNEN vs NEC	MiNEN vs NET	MiNEN vs GCC
		In patients with	In patients with R0	
Shen C.,	Stomach	radical resection,	resection, WD-NET	
2016	Stomach	no difference in	have better OS	
		OS (p=0.102)	(p<0.001)	
Lim S.M., 2016	Stomach	No difference in		
	Stomach	OS (p=0.232)		
D1. IV		No difference in		
Park J.Y.,	Stomach	RFS or in OS $(p =$		
2014		not provided)		
van der	Stomach and	No difference in		
Veen A.,	oesophagus/OGJ	OS (p=0.403)		
2018	осзорнадаз/ОСЈ	ОЗ (р 0.403)		
			WD-NET have better	
Yang M.,	Pancreas	No difference in	OS than	
2015	Tancicas	OS (p=0.071)	NEC/MiNEN	
			(p<0.001)	
Basturk O.,		MiNEN have		
2014	Pancreas	better OS than		
2014		NEC (p=0.0035)		
Zheng Z.,		No difference in		
2019	Biliary tract	RFS (p=0715) or		
2019		OS (p=0.670)		
			WD-NET have better	
Brathwaite	Annondiy		OS than	GCC have better OS than
S., 2016	Appendix		NEC/MiNEN	MiNEN (p<0.001)
			(p<0.001)	
				Trend (although not
			WD-NET have better	statistically significant,
Brathwaite	GEP		OS than	p=0.52) towards a better OS
S., 2016	GEF		NEC/MiNEN	for GCC (13.2 years)
			(p=0.007)	compared to MiNEN (4.1
				years)
Milione M.,	GEP	No difference in		
2018	GEI	OS (p=0.08)		

MiNEN = mixed neuroendocrine non-neuroendocrine neoplasm; NEC = pure neuroendocrine carcinoma; NET = well differentiated neuroendocrine tumour; GCC = goblet cell carcinoid; WD = well differentiated; OS = overall survival; RFS = recurrence free survival; OGJ = oesophagogastric junction; GEP = gastroenteropancreatic tract.